Apalutamide Therapy for Metastatic Prostate Cancer

In this section, apalutamide and androgen Deprivation Therapy (ADT) are recommended for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC). Apalutamide, as a second-generation androgen receptor inhibitor, extends progression-free survival and overall survival when used in combination with ADT. Clinical trials have demonstrated that the combination of apalutamide and ADT is more effective and better [...]